{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:08Z","timestamp":1791298448175,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020207","name":"Health Commission of Sichuan Province","doi-asserted-by":"publisher","award":["21ZD001"],"award-info":[{"award-number":["21ZD001"]}],"id":[{"id":"10.13039\/501100020207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Abnormalities of glucolipid metabolism are critical mechanisms involved in the progression of diabetic kidney disease (DKD). Bile acids have an essential role in regulating glucolipid metabolism. This study investigated the clinicopathological characteristics of DKD patients with different bile acid levels and explored the relationship between bile acids and renal outcomes of DKD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed and evaluated the histopathological features and clinical features of our cohort of 184 patients with type 2 diabetes mellitus and biopsy-proven DKD. Patients were divided into the lower bile acids group (\u22642.8 mmol\/L) and higher bile acids group (&amp;gt;2.8 mmol\/L) based on the cutoff value of bile acids obtained using the time-dependent receiver-operating characteristic curve. Renal outcomes were defined as end-stage renal disease (ESRD). The influence of bile acids on renal outcomes and correlations between bile acids and clinicopathological indicators were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Bile acids were positively correlated with age (r = 0.152; P = 0.040) and serum albumin (r = 0.148; P = 0.045) and negatively correlated with total cholesterol (r = -0.151; P = 0.041) and glomerular class (r = -0.164; P =0.027). During follow-up, 64 of 184 patients (34.78%) experienced progression to ESRD. Lower levels of proteinuria, serum albumin, and bile acids were independently associated with an increased risk of ESRD (hazard ratio, R=5.319; 95% confidence interval, 1.208\u201323.425).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bile acids are an independent risk factor for adverse renal outcomes of DKD patients. The serum level of bile acids should be maintained at more than 2.8 mmol\/L in DKD patients. Bile acid analogs or their downstream signaling pathway agonists may offer a promising strategy for treating DKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.1026995","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T01:26:41Z","timestamp":1665106001000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiang","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuming","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/dc20-1913","article-title":"Worldwide epidemiology of diabetes-related end-stage renal disease, 2000-2015","volume":"44","author":"Cheng","year":"2021","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1602469","article-title":"Trends in chronic kidney disease in China","volume":"375","author":"Zhang","year":"2016","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.kisu.2020.09.001","article-title":"China Kidney disease network (CK-NET) 2016 annual data report","volume":"10","author":"Zhang","year":"2020","journal-title":"Kidney Int supplements."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11020378","article-title":"Therapeutic advances in diabetic nephropathy","volume":"11","author":"Sawaf","year":"2022","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13080","article-title":"The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes","volume":"20","author":"Br\u00f8nden","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.metabol.2017.02.011","article-title":"Bile acid binding resin prevents fat accumulation through intestinal microbiota in high-fat diet-induced obesity in mice","volume":"71","author":"Kusumoto","year":"2017","journal-title":"Metab Clin Exp"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2014.04.016","article-title":"Bile acids are nutrient signaling hormones","volume":"86","author":"Zhou","year":"2014","journal-title":"Steroids"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/MNH.0000000000000374","article-title":"Bile acid receptors and the kidney","volume":"27","author":"Herman-Edelstein","year":"2018","journal-title":"Curr Opin Nephrol hypertension."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0019","article-title":"Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model","volume":"59","author":"Wang","year":"2010","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1642","article-title":"Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy","volume":"56","author":"Jiang","year":"2007","journal-title":"Diabetes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00227","article-title":"Uninephrectomy-induced lipolysis and low-grade inflammation are mimicked by unilateral renal denervation","volume":"7","author":"Arsenijevic","year":"2016","journal-title":"Front Physiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tox.2017.01.007","article-title":"Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation","volume":"378","author":"Zhang","year":"2017","journal-title":"Toxicology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/cd16-0067","article-title":"Standards of medical care in diabetes-2017 abridged for primary care providers","volume":"35","author":"William","year":"2017","journal-title":"Clin diabetes: Publ Am Diabetes Assoc"},{"key":"B15","article-title":"Renal pathology society. Pathologic classification of diabetic nephropathy","volume-title":"J Am Soc Nephrol","author":"Tervaert","year":"2010"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0242-2","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus","volume":"15","author":"Foretz","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz025","article-title":"Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology","volume":"105","author":"Br\u00f8nden","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mam.2017.04.001","article-title":"Bile acids and bariatric surgery","volume":"56","author":"Albaugh","year":"2017","journal-title":"Mol aspects Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2020.08.028","article-title":"Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery","volume":"17","author":"Xu","year":"2021","journal-title":"Surg Obes related diseases: Off J Am Soc Bariatric Surgery."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14683","article-title":"Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2-hour plasma glucose in individuals without diabetes","volume":"24","author":"Wang","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14730","article-title":"Cholecystectomy is associated with dysglycaemia: Cross-sectional and prospective analyses","volume":"24","author":"Sang","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group","volume":"352","author":"Robert","year":"1998","journal-title":"Lancet (London England)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the united kingdom prospective diabetes study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.2230","article-title":"Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes","volume":"172","author":"Coca","year":"2012","journal-title":"Arch Internal Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1900\/RDS.2013.10.88","article-title":"Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients","volume":"10","author":"Chen","year":"2013","journal-title":"Rev Diabetic studies: RDS."},{"key":"B30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrendo.2009.213","article-title":"Residual microvascular risk in diabetes: unmet needs and future directions","volume":"6","author":"Fioretto","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","article-title":"Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study","volume":"58","author":"Muntner","year":"2000","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00869.x","article-title":"Risk factors for renal replacement therapy in the early treatment diabetic retinopathy study (ETDRS), early treatment diabetic retinopathy study report no","volume":"66","author":"Cusick","year":"2004","journal-title":"26. Kidney Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016101123","article-title":"Farnesoid X receptor agonism protects against diabetic tubulopathy: Potential add-on therapy for diabetic nephropathy","volume":"28","author":"Marquardt","year":"2017","journal-title":"J Am Soc Nephrol: JASN"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086553","article-title":"Farnesoid X receptor ligand prevents cisplatin-induced kidney injury by enhancing small heterodimer partner","volume":"9","author":"Bae","year":"2014","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153510","article-title":"Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine","volume":"331","author":"Li","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1032-4","article-title":"TGR5 suppresses high glucose-induced upregulation of fibronectin and transforming growth factor-\u03b21 in rat glomerular mesangial cells by inhibiting RhoA\/ROCK signaling","volume":"54","author":"Xiong","year":"2016","journal-title":"Endocrine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.05.035","article-title":"TGR5 activation suppressed S1P\/S1P2 signaling and resisted high glucose-induced fibrosis in glomerular mesangial cells","volume":"111","author":"Yang","year":"2016","journal-title":"Pharmacol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014121271","article-title":"G Protein-coupled bile acid receptor TGR5 activation inhibits kidney disease in obesity and diabetes","volume":"27","author":"Wang","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0936","article-title":"The long-term effects of metformin on patients with type 2 diabetic kidney disease","volume":"43","author":"Kwon","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1026995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T01:26:48Z","timestamp":1665106008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1026995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":41,"alternative-id":["10.3389\/fendo.2022.1026995"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1026995","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"article-number":"1026995"}}